证券日报网讯12月11日，安杰思在互动平台回答投资者提问时表示，截至2025年12月10日，公司的股东 人数为6294户。 ...

杭州安杰思医学科技股份有限公司 章 程 二〇二五年十二月 | 第一章 | 总则 | 4 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 5 | | | 第三章 | 股份 | 5 | | 第一节 | 股份发行 | 6 | | 第二节 | 股份增减和回购 7 | | | 第三节 | 股份转让 | 9 | | 第四章 | 股东和股东会 10 | | | 第一节 | 股东的一般规定 10 | | | 第二节 | 控股股东和实际控制人 13 | | | 第三节 | 股东会的一般规定 14 | | | 第四节 | 股东会的召集 18 | | | 第五节 | 股东会的提案与通知 19 | | | 第六节 | 股东会的召开 21 | | | 第七节 | 股东会的表决和决议 24 | | | 第五章 | 董事和董事会 | 28 | | 第一节 | 董事的一般规定 28 | | | 第二节 | 董事会 | 32 | | 第三节 | 独立董事 | 38 | | 第四节 | 董事会专门委员会 41 | | | 第六章 | 高级管理人员 43 | | | 第七章 | 财务会计制度、利润分配和审计 45 | ...

证券代码：688581 证券简称：安杰思 公告编号：2025-064 杭州安杰思医学科技股份有限公司 关于变更公司注册资本并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 杭州安杰思医学科技股份有限公司（以下简称"公司"）于 2025 年 12 月 8 日召开了第三届董事会第七次会议，审议通过了《关于变更公司注册资本并修订 <公司章程>的议案》，上述议案尚需提交股东会审议。现将有关情况公告如下： 因公司已完成 2023 年限制性股票激励计划首次授予部分第二个归属期及预 留授予部分第一个归属期的归属，本次归属股票的数量为 143,285 股，并已于 2025 年 10 月 9 日在中国证券登记结算有限责任公司上海分公司完成登记。本次 归属后，公司注册资本由 80,978,794 元增加至 81,122,079 元，股份总数由 80,978,794 股增加至 81,122,079 股。 公司结合前述限制性股票归属登记情况，对《公司章程》中的相关条款修改 如下： 效期限为自公司股东会审议通过之日起至本次 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-066 杭州安杰思医学科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 12 月 16 日（星期二）15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 12 月 09 日（星期二）至 12 月 15 日（星期一）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过 IR@bioags.com 进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 杭州安杰思医学科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-065 杭州安杰思医学科技股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第三次临时股东会 召开日期时间：2025 年 12 月 24 日 15 点 30 分 召开地点：杭州市临平区兴中路 389 号三楼 302 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》 等有关规定执行。 （七） 涉及公开征集股东投票权 无 二、 会议审议事项 网络投票起止时间：自2025 年 12 月 24 日 至2025 年 12 月 ...

Core Viewpoint - The company's stock performance is influenced by a combination of macroeconomic environment, market sentiment, and industry cycles, while maintaining stable orders in the fourth quarter [1] Group 1 - The company is focusing on the development of its core business through technological innovation, cost control, and market expansion [1] - The company is actively working to enhance its core competitiveness [1]

证券日报网讯安杰思11月24日在互动平台回答投资者提问时表示，截至2025年11月20日，公司的股东人 数为6401户。 ...

Group 1: Fund Performance and Trends - The report analyzes the evolution and current status of performance benchmarks for public funds in China and the US, highlighting the divergence in performance of active equity funds from their benchmarks and potential causes [1][7][10] - It notes that the number of active equity funds in both markets is primarily based on broad indices, with a trend towards diversification observed in the last two years. Approximately 7.24% (239 funds) of China's active equity funds have benchmarks not included in the benchmark library, which may face adjustment pressures [10][11] - The report concludes that the deviation of active equity funds in China is significantly higher than in the US, attributing this to differences in fund sales models and the diversity of ETF products [10][11] Group 2: Securities Industry Insights - The report discusses the merger of CICC with Dongxing Securities and Xinda Securities, indicating a continuation of supply-side reforms in the securities industry. This merger is expected to optimize the industry structure and enhance CICC's competitive position [12][13] - Following the merger, CICC's total asset scale is projected to reach 1 trillion yuan, elevating its ranking among listed securities firms. The merger is anticipated to improve CICC's brokerage and asset management capabilities significantly [14] - The report highlights a mismatch between the profitability and valuation of the securities sector, suggesting substantial room for valuation recovery, with recommendations for investing in large, undervalued securities firms [15] Group 3: Pharmaceutical Sector Analysis - The report tracks the performance of Pizhou Pharmaceutical, noting a revenue decline of 11.93% year-on-year for the first three quarters of 2025, with a significant drop in net profit. However, it anticipates a potential improvement in gross margin due to falling raw material prices [17][18] - Pizhou's product strategy focuses on core products while expanding into cosmetics, with notable sales growth in its flagship beauty product. The company is also advancing its R&D pipeline with new drug developments [18][19] - The investment recommendation suggests an EPS forecast of 4.04, 4.40, and 4.82 yuan for 2025, 2026, and 2027, respectively, maintaining a "buy" rating due to the unique attributes of its core products [18][19] Group 4: Express Delivery Sector Overview - The report reviews Shentong Express's operational data for October 2025, indicating a year-on-year revenue increase of 11.84% and a positive growth trend in express delivery volume [20][21] - The average service price per delivery has risen, contributing to the overall revenue growth, with expectations for continued strong performance in 2025 [20][21] - The forecast for Shentong's EPS for 2025-2027 is set at 0.89, 1.22, and 1.48 yuan, respectively, with a "buy" rating based on the anticipated growth trajectory [21]

Core Points - The company, Shanghai Xinxiangwei Electronics Co., Ltd., announced a share reduction plan by its shareholder, Kexin Chip (Hong Kong) Co., Ltd. [2] - Before the implementation of the reduction plan, Kexin Chip held 28,619,320 shares, accounting for 6.23% of the company's total share capital [2] - As of November 12, 2025, Kexin Chip has reduced its holdings by 4,595,294 shares, which is 1% of the total share capital, completing the reduction plan [2] - After the reduction, Kexin Chip holds 24,024,026 shares, representing 5.23% of the total share capital [2]

Core Viewpoint - Anjieshi, a leading domestic endoscopic medical device company, focuses on the research, production, and sales of minimally invasive endoscopic diagnostic and therapeutic instruments, showcasing technological innovation and product differentiation advantages [1] Group 1: Company Overview - Anjieshi was established on December 6, 2010, and was listed on the Shanghai Stock Exchange on May 19, 2023, with its registered and operational base in Hangzhou, Zhejiang Province [1] - The company operates in the pharmaceutical and biological industry, specifically in medical devices and consumables, and is categorized under several concept sectors including medical devices and specialized innovation [1] Group 2: Financial Performance - For Q3 2025, Anjieshi reported a revenue of 459 million yuan, ranking 31st among 50 companies in the industry, while the industry leader, Yingke Medical, achieved a revenue of 7.425 billion yuan [2] - The net profit for the same period was 177 million yuan, placing the company 21st in the industry, with the top performer, Lepu Medical, reporting a net profit of 999.6 million yuan [2] Group 3: Financial Ratios - Anjieshi's debt-to-asset ratio stood at 4.17% in Q3 2025, down from 4.67% year-on-year, significantly lower than the industry average of 23.66%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 70.51%, slightly down from 72.13% year-on-year, but still above the industry average of 48.78%, reflecting robust profitability [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 16.49% to 5,567, while the average number of circulating A-shares held per shareholder decreased by 14.15% to 7,439.63 [5] - Notable new shareholders include Ping An Low Carbon Economy Mixed A and Hong Kong Central Clearing Limited, indicating growing interest in the company [5] Group 5: Business Outlook - Short-term performance may face pressure due to decreased purchasing willingness among distributors ahead of centralized procurement in some regions and the impact of US-China tariffs on the US market [6] - Despite challenges, the company is launching new products such as replaceable hemostatic clips and bipolar electrosurgical knives, which are expected to enhance market share [6] - The company aims to expand its domestic hospital coverage, which exceeded 2,540 hospitals by mid-2025, and is progressing with local operations in overseas markets [6][7] - Revenue projections for 2025 to 2027 are 763 million, 936 million, and 1.144 billion yuan, with net profits of 320 million, 378 million, and 442 million yuan respectively [6][7]